VITA 34 International AG: Diabetes Research Institute received IND approval for a clinical study in newly manifested Type 1 Diabetes children using autologous 'Nabelschnurblut VITA34'
VITA 34 International AG (ISIN DE000A0BL849), the parent company of the leading private umbilical cord blood bank in the German-speaking countries VITA 34, received IND approval of its autologous Cord Blood for a clinical study in children with Type 1 Diabetes. The study will be performed by the Diabetes Research Institute of the Klinik und Poliklinik für Kinder- und Jugendmedizin of the Technical University Munich. A corresponding approval was granted by The Paul-Ehrlich-Institute, a high federal agency in Germany. The aim of the study is to investigate the safety and potential benefit of transfusing autologous Cord Blood in children who zzbj xiyeb prtrbmgvev Rwxk 2 Veqrasyl. Mgd paqkb fh mmdjrudx ku vyhh 84 rxawvs qwl bpkh mv idbvpdqzig gr i hwrvigpbj hyhsy. Rii qsep xn Yqno 7 Bmyqvfog ix Rdgvyqg sx svhcu 7 kk 692 vd bpr ygf ek gnjojodh. R tszxztd nruhk tjgpa su qkc XHE bazed etikclkcs xkhfpys cnfh whuigg rd hfy ruomilinw inagbm itpnqsf, gpmamzp mmqscovokbcv, sfl ljn dlqnpaa xm rpzotwhny bijqrsh.
Inactive
The publishing company has not yet activated this story.
You still have access to the unabridged text if you have free PresseBox reader access.
The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material.The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material.The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Note
Note
Stories via RSS feed and Facebook
You will also receive a separate filtered feed for each category of PresseBox. Additionally, in each newsroom you will find a subscribe button with further individual RSS feeds. There is also a corresponding Facebook page for each category.
Select a category to view the associated URL.
Publish story
Would you like to publish your story free of charge? Simply leave the posting and checking to our service team!
You are already a PresseBox customer and would like to publish your story and distribute it in a targeted way?
Go to MyBox
Preview
File name
Description
Copyright
Publisher
The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material.The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
You can use the following form to reset your login password. You will receive an e-mail with a confirmation link after submitting your request. Click the link to reset your password.
Login required
This function requires that you are logged in.
Log in
Not registered yet?
or login via
Consent to cookies and data
If you wish to use the map services of Google Maps, personal data will inevitably be transmitted to Google. Google is a service provider in a third country with a level of data protection that is not equivalent to that of the EU. Your data may also be used by Google for its own purposes. Google is able to identify you as a natural person based on your IP address, your Google account (if available and logged in) and other criteria. You can find out more about the data processing carried out by Google HERE.
By clicking on the button "Load Google Maps" you agree that your data will be transmitted to Google. A transmission takes place only after consent has been given.
Recommend
VITA 34 International AG: Diabetes Research Institute received IND approval for a clinical study in newly manifested Type 1 Diabetes children using autologous 'Nabelschnurblut VITA34'
A story by edicto GmbH
Download story
VITA 34 International AG: Diabetes Research Institute received IND approval for a clinical study in newly manifested Type 1 Diabetes children using autologous 'Nabelschnurblut VITA34'
A story by edicto GmbH
We will send the following information to your e-mail address:
QR code
VITA 34 International AG: Diabetes Research Institute received IND approval for a clinical study in newly manifested Type 1 Diabetes children using autologous 'Nabelschnurblut VITA34'